Neoadjuvant therapy with trametinib and dabrafenib in high risk resectable BRAF-mutant melanoma

Rodabe N. Amaria, MD from the University of Texas MD Anderson Cancer Center, Houston, TX summarizes results on a recent randomized Phase II clinical trial of neoadjuvant treatment with BRAF and MEK in... Author: VJOncology Added: 02/16/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts